Literature DB >> 9064326

Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice.

R Mueller1, T Krahl, N Sarvetnick.   

Abstract

Diabetes in nonobese diabetic (NOD) mice is a T cell-dependent autoimmune disease. The destructive activities of autoreactive T cells have been shown to be tightly regulated by effector molecules. In particular, T helper (Th) 1 cytokines have been linked to diabetes pathogenesis, whereas Th2 cytokines and the cells that release them have been postulated to be protective from disease. To test this hypothesis, we generated transgenic NOD mice that express interleukin (IL) 4 in their pancreatic beta cells under the control of the human insulin promoter. We found that transgenic NOD-IL-4 mice, both females and males, were completely protected from insulitis and diabetes. Induction of functional tolerance to islet antigens in these mice was indicated by their inability to reject syngeneic pancreatic islets and the failure of diabetogenic spleen cells to induce diabetes in transgenic NOD-IL-4 recipients. Interestingly, however, islet expression of IL-4 was incapable of preventing islet rejection in overtly diabetic NOD recipient mice. These results demonstrate that the Th2 cytokine IL-4 can prevent the development of autoimmunity and destructive autoreactivity in the NOD mouse. Its ability to regulate the disease process in the periphery also indicates that autoimmune diabetes in NOD mice is not a systemic disease, and it can be modulated from the islet compartment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9064326      PMCID: PMC2192796          DOI: 10.1084/jem.184.3.1093

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  39 in total

Review 1.  The murine autoimmune diabetes model: NOD and related strains.

Authors:  H Kikutani; S Makino
Journal:  Adv Immunol       Date:  1992       Impact factor: 3.543

2.  Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy.

Authors:  T Wang; B Singh; G L Warnock; R V Rajotte
Journal:  Diabetes       Date:  1992-01       Impact factor: 9.461

3.  Memory effectors: a potent, IL-4-secreting helper T cell population that develops in vivo after restimulation with antigen.

Authors:  L M Bradley; D D Duncan; K Yoshimoto; S L Swain
Journal:  J Immunol       Date:  1993-04-15       Impact factor: 5.422

4.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase.

Authors:  S Baekkeskov; H J Aanstoot; S Christgau; A Reetz; M Solimena; M Cascalho; F Folli; H Richter-Olesen; P De Camilli; P D Camilli
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

5.  A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages.

Authors:  F Y Liew; Y Li; A Severn; S Millott; J Schmidt; M Salter; S Moncada
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

6.  Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors.

Authors:  S W Christianson; L D Shultz; E H Leiter
Journal:  Diabetes       Date:  1993-01       Impact factor: 9.461

7.  Autoimmune diabetes as a consequence of locally produced interleukin-2.

Authors:  W R Heath; J Allison; M W Hoffmann; G Schönrich; G Hämmerling; B Arnold; J F Miller
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

8.  IL-4 suppresses cytokine gene expression induced by IFN-gamma and/or IL-2 in murine peritoneal macrophages.

Authors:  S Gautam; J M Tebo; T A Hamilton
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

9.  Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice.

Authors:  P Sempé; P Bédossa; M F Richard; M C Villà; J F Bach; C Boitard
Journal:  Eur J Immunol       Date:  1991-05       Impact factor: 5.532

10.  Interleukin (IL) 4, in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8+ TC1 cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines.

Authors:  S Sad; T R Mosmann
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  60 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 3.  Allograft rejection results from a failed attempt by the immune system to protect foreign tissue.

Authors:  D S Hall; E Roberts; J Davies
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 4.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 5.  Cytokine-based immunointervention in the treatment of autoimmune diseases.

Authors:  L Adorini
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

6.  IL-4 and IL-10 modulate autoimmune haemolytic anaemia in NZB mice.

Authors:  A-R Youssef; C-R Shen; C-L Lin; R N Barker; C J Elson
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

7.  Cannabidiol arrests onset of autoimmune diabetes in NOD mice.

Authors:  Lola Weiss; Michael Zeira; Shoshana Reich; Shimon Slavin; Itamar Raz; Raphael Mechoulam; Ruth Gallily
Journal:  Neuropharmacology       Date:  2007-07-17       Impact factor: 5.250

Review 8.  A gene therapy approach to treatment of autoimmune disease.

Authors:  C M Seroogy; C G Fathman
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

9.  IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit.

Authors:  Kotaro Sasaki; Angela D Pardee; Hideho Okada; Walter J Storkus
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

10.  AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice.

Authors:  Khaja K Rehman; Massimo Trucco; Zhong Wang; Xiao Xiao; Paul D Robbins
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.